Tekla Capital Management LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 184 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.

Quarter-by-quarter ownership
Tekla Capital Management LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2023$575,861
-17.6%
52,0670.0%0.02%
-14.8%
Q1 2023$699,260
+8.6%
52,0670.0%0.03%
+12.5%
Q4 2022$644,069
-11.3%
52,0670.0%0.02%
-20.0%
Q3 2022$726,000
+1.0%
52,0670.0%0.03%
+7.1%
Q2 2022$719,000
-15.1%
52,0670.0%0.03%
-6.7%
Q1 2022$847,000
-0.1%
52,0670.0%0.03%
+11.1%
Q4 2021$848,000
+9.7%
52,0670.0%0.03%
+8.0%
Q3 2021$773,000
-49.8%
52,067
-32.4%
0.02%
-50.0%
Q2 2021$1,539,000
-13.5%
77,0670.0%0.05%
-18.0%
Q1 2021$1,779,000
-6.6%
77,0670.0%0.06%
-9.0%
Q4 2020$1,904,000
-40.4%
77,0670.0%0.07%
-44.2%
Q3 2020$3,195,000
-13.5%
77,0670.0%0.12%
-14.9%
Q2 2020$3,692,000
+70.4%
77,067
+123.9%
0.14%
+43.9%
Q1 2020$2,167,000
-49.2%
34,4140.0%0.10%
-39.1%
Q4 2019$4,265,000
+86.7%
34,4140.0%0.16%
+61.0%
Q3 2019$2,284,000
-46.7%
34,414
-36.1%
0.10%
-42.9%
Q2 2019$4,285,000
-35.4%
53,857
-9.1%
0.18%
-34.9%
Q1 2019$6,631,000
+393.0%
59,275
+344.1%
0.27%
+363.8%
Q4 2018$1,345,000
-81.2%
13,348
-89.2%
0.06%
-77.3%
Q3 2017$7,151,000123,2000.26%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2020
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$9,514,0001.49%
CM Management, LLC 45,000$668,0000.50%
EULAV Asset Management 660,000$9,801,0000.26%
DLD Asset Management, LP 225,200$3,346,0000.24%
Virtus ETF Advisers LLC 21,387$318,0000.14%
GSA CAPITAL PARTNERS LLP 79,145$1,175,0000.12%
Hennion & Walsh Asset Management, Inc. 136,720$2,030,0000.11%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$2,507,0000.08%
Inspire Investing, LLC 31,868$473,0000.06%
DUALITY ADVISERS, LP 51,196$760,0000.06%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders